中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2064 records (took 0.189 seconds)

    COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES
    93.
    发明申请
    COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES 有权

    公开(公告)号：US20220204525A1

    公开(公告)日：2022-06-30

    申请号：US17694635

    申请日：2022-03-14

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Koichiro FUKUOKA ,  Kazuhiro MIWA ,  Tsuyoshi SASAKI ,  Fumiya KOMURA

    IPC: C07D495/04 ,  C07D333/38 ,  C07D409/12

    Abstract: The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrirnidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1′-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.

    TREATMENT OF CNS CONDITIONS
    95.
    发明申请
    TREATMENT OF CNS CONDITIONS 有权

    公开(公告)号：US20220168294A1

    公开(公告)日：2022-06-02

    申请号：US17673072

    申请日：2022-02-16

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Toshiya Nishi ,  Shinichi KONDO

    IPC: A61K31/4545 ,  A61P25/08

    Abstract: Aspects of the present invention relate to a method of treating an epileptic encephalopathy in a mammal in need thereof, comprising administering a composition comprising an effective amount of (4-benzyl-4-hydroxypiperidin-1-yl) (2,4′-bipyridin-3-yl)methanone or a pharmaceutically acceptable salt thereof to the mammal.

    Anti-plasma kallikrein antibodies
    97.
    发明授权
    Anti-plasma kallikrein antibodies 有权

    公开(公告)号：US11299553B2

    公开(公告)日：2022-04-12

    申请号：US16199453

    申请日：2018-11-26

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Andrew Nixon ,  Jon A. Kenniston ,  Stephen R. Comeau

    IPC: C07K16/40 ,  C12N15/52

    Abstract: Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

    METHOD FOR DETECTING CELLS
    99.
    发明申请
    METHOD FOR DETECTING CELLS 有权

    公开(公告)号：US20220099670A1

    公开(公告)日：2022-03-31

    申请号：US17427222

    申请日：2021-01-31

    Applicant: Kyoto University ,  TAKEDA PHARMACEUTICAL COMPANY LIMITED

    Inventor： Shin KANEKO ,  Shoichi IRIGUCHI ,  Keiko SEKIYA ,  Yoshiaki KASSAI

    IPC: G01N33/567 ,  C12N5/00 ,  C12N5/0784 ,  G01N33/50

    Abstract: Disclosed is a method for detecting regulatory dendritic cells, the method comprising step a: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step b: identifying regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Also disclosed is a method for producing a cell population enriched for regulatory dendritic cells, the method comprising step 1: detecting the presence or absence of one or more types of molecules on a cell surface in a cell population that comprises regulatory dendritic cells; and step 2: obtaining a cell population enriched for regulatory dendritic cells on the basis of the presence or absence of the one or more types of molecules. Further disclosed is a cell population enriched for regulatory dendritic cells obtained by the method.

    CATIONIC LIPID
    100.
    发明申请
    CATIONIC LIPID 有权

    公开(公告)号：US20220098142A1

    公开(公告)日：2022-03-31

    申请号：US17267179

    申请日：2019-08-08

    Applicant: Takeda Pharmaceutical Company Limited

    Inventor： Satoru Matsumoto ,  Yoshimasa Omori ,  Masahiro Mineno ,  Yasuhiro Sawai ,  Nozomu Kakimoto ,  Yusutaka Hoashi

    IPC: C07C229/12 ,  C12N15/113 ,  A61K9/51

    Abstract: The present invention provides a technique capable of transferring an active ingredient, particularly, a nucleic acid, to a cell with excellent efficiency and a cationic lipid for use in this technique, etc. The cationic lipid of the present invention is a compound represented by the formula (I) or a salt thereof. n1 represents an integer of 2 to 6, n2 represents an integer of 0 to 2, n3 represents an integer of 0 to 2, L represents —C(O)O— or —NHC(O)O—, Ra represents a linear C5-13 alkyl group, a linear C13-17 alkenyl group or a linear C17 alkadienyl group, Rb represents a linear C2-9 alkyl group, Rc represents a hydrogen atom or a linear C2-9 alkyl group, Rd represents a hydrogen atom or a linear C2-9 alkyl group, Re represents a linear C2-9 alkyl group, and Rf represents a linear C2-9 alkyl group.

Patent Agency Ranking